The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

European regulators have cleared Anocca to begin a Phase I/II umbrella trial of its lead targeted T-cell receptor (TCR) therapy ANOC-001 and other pipeline candidates in certain advanced pancreatic ...

Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone in the company’s transition ...

SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- c/side, a cybersecurity company specializing in browser-side third-party scripts, is now available in AWS Marketplace, a digital catalog with ...

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

Archery has struggled for recognition in Nigeria for decades. Now, a governance crisis threatens its very existence.

With CAR-TCR therapies on the cusp of achieving global approval, there are still many bottlenecks that are preventing this from becoming the ‘sell-out’ therapy that the field had hoped for ...